MAPT and Alzheimer disease: Average NDEV P-S396-tau levels were significantly higher (p < 0.05) in mild-to-moderate AD (CD81-adjusted levels: 34.13 pg/ml), but not in advanced AD (CD81-adjusted levels: 28.82 pg/ml), than in controls (Fig. 1d).